**Everolimus** LUNA



PRELIMINARY SCORE  CURATIVE  CVerall Survival / Disease-Free Survival / Pathological Complete Response  NON-CURATIVE  NON-CURATIVE  NON-CURATIVE  Overall Survival  ADJUSTMENTS  Quality of life  Progression-Free Survival  Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate  Serious and disabiling adverse effects  Overall Survival / Disease-Free Survival / Pathological Complete Response  Overall Survival / Disease-Free Survival / Pathological Complete Response  Nor-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate  Nor-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate  Nor-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate  Nor-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate  Nor-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate  Nor-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate  Nor-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate  Nor-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate  Nor-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate  Nor-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate  Nor-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate  Nor-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate  Nor-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate  Nor-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate  Nor-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate  Nor-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate		
CURATIVE  Overall Survival / Disease-Free Survival / Pathological Complete Response  NON-CURATIVE  NON-CURATIVE  Overall Survival  Overall Survival  Non-inferiority (improved Quality of Life or Reduced Adverse Events) / Response Rate  Progression-Free Survival  Non-inferiority (improved Quality of Life or Reduced Adverse Events) / Response Rate  Overall Survival / Disease-Free Survival / Pathological Complete Response  Overall Survival / Disease-Free Survival / Pathological Complete Response  INFORMATION  Tumour type: Endocrine Tumours Therapeutic Indication: Unresectable or metastatic, well-differentiated (Grade 1 or Grade 2) not processive disease Experimental Arm: Everolimus	Everolimus LUNA	Everolimus LUNA
NON-CURATIVE  NON-CURATIVE  NON-CURATIVE  NON-CURATIVE  Overall Survival / Disease-Free Survival / Pathological Complete Response  Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate  Serious and disabling adverse effects  Overall Survival / Disease-Free Survival / Pathological Complete Response Rate  Overall Survival / Disease-Free Survival / Pathological Complete Response Rate  Overall Survival / Disease-Free Survival / Pathological Complete Response  Overall Survival / Disease-Free Survival / Pathological Complete Response Overall Survival / Disease-Free Survival / Pathological Complete Response Overall Survival / Disease-Free Survival / Pathological Complete Response Overall Survival / Disease-Free Survival / Pathological Complete Response Overall Survival / Disease-Free Survival / Pathological Complete Response Rate / Duration of Response Overall Survival / Disease-Free Survival / Pathological Complete Response Rate / Duration of Response Rate / Duration of Response Overall Survival / Disease-Free Survival / Pathological Complete Response Rate / Duration of Rate / Dur	PRELIMINARY SCORE	FINAL SCORE
NON-CURATIVE  ADJUSTMENTS  Quality of life  Progression-Free Survival  Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate  Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate  Overall Survival / Disease-Free Survival / Pathological Complete Response  Overall Survival / Disease-Free Survival / Pathological Complete Response  INFORMATION  Tumour type: Endocrine Tumours Therapeutic Indication: Unresectable or metastatic, well-differentiated (Grade 1 or Grade 2) non-functional neuroendocrine tumours of gastrointestinal or lung origin in adults with progressive disease Experimental Arm: Everolimus	CURATIVE	CURATIVE
NON-CURATIVE  ADJUSTMENTS  Quality of life  Progression-Free Survival  Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate  Serious and disabling adverse effects  Overall Survival / Disease-Free Survival / Pathological Complete Response  Overall Survival / Disease-Free Survival / Pathological Complete Response  INFORMATION  Tumour type: Endocrine Tumours Therapeutic Indication: Unresectable or metastatic, well-differentiated (Grade 1 or Grade 2) non-functional neuroendocrine tumours of gastrointestinal or lung origin in adults with progressive disease Experimental Arm: Everolimus		
ADJUSTMENTS  Overall Survival  Overall Survival  Overall Survival  Progression-Free Survival  Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate  Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate  Overall Response Rate / Duration of Response  Overall Survival / Disease-Free Survival / Pathological Complete Response  INFORMATION  Tumour type: Endocrine Tumours  Therapeutic Indication: Unresectable or metastatic, well-differentiated (Grade 1 or Grade 2) non-functional neuroendocrine tumours of gastrointestinal or lung origin in adults with progressive diseases  Experimental Arm: Everolimus		Overall Survival / Disease-Free Survival / Pathological Complete Response
ADJUSTMENTS  Overall Survival  Progression-Free Survival  Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate  Serious and disabling adverse effects  Overall Response Rate / Duration of Response  Overall Survival / Disease-Free Survival / Pathological Complete Response  Overall Survival / Disease-Free Survival / Pathological Complete Response  INFORMATION  Tumour type: Endocrine Tumours Therapeutic Indication: Unresectable or metastatic, well-differentiated (Grade 1 or Grade 2) non-functional neuroendocrine tumours of gastrointestinal or lung origin in adults with progressive disease  Experimental Arm: Everolimus	NON-CURATIVE	
ADJUSTMENTS  Quality of life  Progression-Free Survival  Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate  Serious and disabling adverse effects  3  Overall Response Rate / Duration of Response  Overall Survival / Disease-Free Survival / Pathological Complete Response  INFORMATION  Tumour type: Endocrine Tumours Therapeutic Indication: Unresectable or metastatic, well-differentiated (Grade 1 or Grade 2) non-functional neuroendocrine tumours of gastrointestinal or lung origin in adults with progressive disease  Experimental Am: Everolimus	DES	NON-CURATIVE
ADJUSTMENTS  Quality of life  Progression-Free Survival  Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate  Serious and disabling adverse effects  Overall Response Rate / Duration of Response  Overall Survival / Disease-Free Survival / Pathological Complete Response  INFORMATION  Tumour type: Endocrine Tumours Therapeutic Indication: Unresectable or metastatic, well-differentiated (Grade 1 or Grade 2) non-functional neuroendocrine tumours of gastrointestinal or lung origin in adults with progressive disease Experimental Arm: Everolimus		
Progression-Free Survival  Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate  Serious and disabling adverse effects  Overall Response Rate / Duration of Response  Overall Survival / Disease-Free Survival / Pathological Complete Response  INFORMATION  Tumour type: Endocrine Tumours Therapeutic Indication: Unresectable or metastatic, well-differentiated (Grade 1 or Grade 2) non-functional neuroendocrine tumours of gastrointestinal or lung origin in adults with progressive disease Experimental Arm: Everolimus	ADJUSTMENTS	Overall Survival
Progression-Free Survival  Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate  Serious and disabling adverse effects  Overall Response Rate / Duration of Response  Overall Survival / Disease-Free Survival / Pathological Complete Response  INFORMATION  Tumour type: Endocrine Tumours Therapeutic Indication: Unresectable or metastatic, well-differentiated (Grade 1 or Grade 2) non-functional neuroendocrine tumours of gastrointestinal or lung origin in adults with progressive disease Experimental Arm: Everolimus	Quality of life	
Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate  Serious and disabling adverse effects  Overall Response Rate / Duration of Response  Overall Survival / Disease-Free Survival / Pathological Complete Response  INFORMATION  Tumour type: Endocrine Tumours Therapeutic Indication: Unresectable or metastatic, well-differentiated (Grade 1 or Grade 2) non-functional neuroendocrine tumours of gastrointestinal or lung origin in adults with progressive disease Experimental Arm: Everolimus		Progression-Free Survival
Serious and disabling adverse effects  Overall Response Rate / Duration of Response  Overall Survival / Disease-Free Survival / Pathological Complete Response  INFORMATION  Tumour type: Endocrine Tumours Therapeutic Indication: Unresectable or metastatic, well-differentiated (Grade 1 or Grade 2) non-functional neuroendocrine tumours of gastrointestinal or lung origin in adults with progressive disease Experimental Arm: Everolimus		
Overall Response Rate / Duration of Response  Overall Survival / Disease-Free Survival / Pathological Complete Response  INFORMATION  Tumour type: Endocrine Tumours Therapeutic Indication: Unresectable or metastatic, well-differentiated (Grade 1 or Grade 2) non-functional neuroendocrine tumours of gastrointestinal or lung origin in adults with progressive disease Experimental Arm: Everolimus	Springs and disabling advarsa offacts	γ, γ, ε
Other adjustments  INFORMATION  Tumour type: Endocrine Tumours Therapeutic Indication: Unresectable or metastatic, well-differentiated (Grade 1 or Grade 2) non-functional neuroendocrine tumours of gastrointestinal or lung origin in adults with progressive disease Experimental Arm: Everolimus	Serious and disability adverse effects	
Tumour type: Endocrine Tumours Therapeutic Indication: Unresectable or metastatic, well-differentiated (Grade 1 or Grade 2) non-functional neuroendocrine tumours of gastrointestinal or lung origin in adults with progressive disease Experimental Arm: Everolimus		Overall Survival / Disease-Free Survival / Pathological Complete Response
Control 7 time. Cingle aim	Other adjustments	INFORMATION  Tumour type: Endocrine Tumours Therapeutic Indication: Unresectable or metastatic, well-differentiated (Grade 1 or Grade 2) non-functional neuroendocrine tumours of gastrointestinal or lung origin in adults with progressive disease Experimental Arm: Everolimus

